-transparent.png){kind=logo}
Tumor immunology studies have been utilized for development of a blocking factor assay for therapy monitoring in ovarian cancer. The blocking factor index was defined as the arithmetic difference between assays conducted in the presence and absence of the patient's serum compared to incubations with normal control lymphocytes. Eighteen advanced ovarian epithelial malignancies have shown blocking factor activity during treatment. Blocking factor has abated in eight patients whose clinical disease completely regressed. Chemotherapy was discontinued after 18 to 24 months. In 10 patients, blocking factor persisted and chemotherapy has been continued. Some of these patients showed decreasing blocking factor; others have shown increases, which led to death due to disseminated disease in four cases. Blocking factor activity was found to correlate with tumor growth.
R A Pattillo, and
A C Ruckert, and
M T Story, and
R F Mattingly
September 1991,
Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao,
R A Pattillo, and
A C Ruckert, and
M T Story, and
R F Mattingly
January 1978,
Gynecologic and obstetric investigation,
R A Pattillo, and
A C Ruckert, and
M T Story, and
R F Mattingly
May 1978,
Chinese medical journal,
R A Pattillo, and
A C Ruckert, and
M T Story, and
R F Mattingly
January 1990,
Immunology series,
R A Pattillo, and
A C Ruckert, and
M T Story, and
R F Mattingly
January 2018,
Technology in cancer research & treatment,
R A Pattillo, and
A C Ruckert, and
M T Story, and
R F Mattingly
July 1987,
Ceskoslovenska gynekologie,
R A Pattillo, and
A C Ruckert, and
M T Story, and
R F Mattingly
November 1976,
Obstetrics and gynecology,
R A Pattillo, and
A C Ruckert, and
M T Story, and
R F Mattingly
July 1978,
Harefuah,
R A Pattillo, and
A C Ruckert, and
M T Story, and
R F Mattingly
January 1994,
Oncology,
R A Pattillo, and
A C Ruckert, and
M T Story, and
R F Mattingly
September 1972,
British medical journal,
